A5064577386- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Cancer Research and Treatments
- 3D Printing in Biomedical Research
- Latin American and Latino Studies
- Diaspora, migration, transnational identity
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Migration, Ethnicity, and Economy
Dublin City University
2019-2025
Abstract The RAD51-BRCA2 interaction is central to DNA repair through homologous recombination. Emerging evidence indicates RAD51 overexpression and its correlation with chemoresistance in various cancers, suggesting inhibition as a compelling avenue for intervention. We previously showed that combining olaparib (a PARP inhibitor (PARPi)) RS -35d BRCA2-RAD51 inhibitor) was efficient killing pancreatic ductal adenocarcinoma (PDAC) cells. However, impaired cell viability even when administered...
Abstract With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) is the deadliest all cancers. The rapid mortality makes PDAC difficult to research, and inspires resolve create reliable, tractable cellular models for preclinical cancer research. Organoids are increasingly used model as they maintain differentiation status, molecular genomic signatures original tumour. In this paper, we present novel methodologies experimental approaches develop organoids from PDX...
Background. Pancreatic cancer is a devastating disease; its lethality related to rapid growth and tendency invade adjacent organs metastasize at an early stage. Objective. The aim of this study was identify miRNAs their gene targets involved in the invasive phenotype pancreatic better understand biological behaviour progression disease. Methods. miRNA profiling performed isogenic matched high low-invasive subclones derived from MiaPaCa-2 cell line validated panel lines, tumour, normal...
Pancreatic cancer is a highly lethal disease. Therapeutic resistance to chemotherapy major cause of treatment failure and recurrence in pancreatic cancer. Organoids derived from stem cells (CSC) are promising models for the advancement personalised therapeutic responses inform clinical decisions. However, scaling-up 3D organoids high-throughput screening time-consuming costly. Here, we successfully developed organoid-derived cell lines (2.5D) organoids; were then expanded recapitulated back...
Pancreatic ductal adenocarcinoma (PDAC) is the deadliest of all cancers, with a five-year survival rate 8%. Decades research has done little to improve patient outcomes. To identify key therapeutic strategies, appropriate preclinical models are critical for testing efficacy drugs or downstream functional genomic analysis. Current methods growing PDAC established cell lines in 2D monolayer do not fully represent how tumor cells grow vivo as they fail recapitulate physiology tumors due...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is the deadliest of all cancers, with a five-year survival rate 8%. Decades research has done little to improve patient outcomes. To identify key therapeutic strategies, appropriate preclinical models are critical for testing efficacy drugs or downstream functional genomic analysis. Current methods growing PDAC established cell lines in 2D monolayer do not fully represent how tumor cells grow vivo as they fail recapitulate physiology tumors...